Health

Results: 6937-6948 of 8097

Women's Health Remains in Crisis Worldwide Even as COVID-19 Pandemic Wanes

Parse Biosciences Acquires Biomage

PR Newswire associated0

Agepha Pharma and Caristo Diagnostics Team Up to Fight Coronary Inflammation

PR Newswire associated0

FIRST PATIENTS ENROLLED IN THE GORE VBX FORWARD CLINICAL STUDY

PR Newswire associated0

Unchained Labs has the inside track on Lentivirus RNA detection, launches new Leprechaun application!

PR Newswire associated0

Epitomee® Announces Successful Completion of Pivotal Clinical Trial for Innovative Weight Loss Capsule

U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

KBI Biopharma, Inc. and Argonaut Manufacturing Services, Inc. Forge Strategic Alliance to Support Global Biopharmaceutical Companies with Integrated Drug Substance and Drug Product Solutions

Single Use Support continues to grow, expanding its team by 40%

On January 11th, trailblazing medical technology company Xenco Medical unveiled its convergent technology bridging Digital Health and Biomaterials by showcasing its TrabeculeX Continuum™ at the 2024 Consumer Electronics Show in Las Vegas, Nevada. Comprising the TrabeculeX Bioactive Matrix™ and the TrabeculeX Recovery App™, the TrabeculeX Continuum is the first technology-enabled bridge between orthobiologics and digital health, unifying a patient’s biomaterial implantation and postoperative journey. (Graphic: Business Wire)

Xenco Medical Unveils the TrabeculeX Continuum, a Breakthrough Convergence of Digital Health and Biomaterials, at CES 2024 in Las Vegas, the World’s Largest Technology Conference

Envision Pharma Group Appoints Life Sciences Industry Veteran Alice Choi as President, Integrated Medical Capabilities and Solutions (IMC)

Aviceda Therapeutics Announces Topline Data from Part 1 of the Phase 2/3 SIGLEC Clinical Trial for AVD-104, Demonstrating Positive Safety and Early Clinical Efficacy in Patients with Geographic Atrophy